Search: onr:"swepub:oai:DiVA.org:uu-452310" >
Androgen deprivatio...
Androgen deprivation monotherapy usage in non-metastatic prostate cancer : results from eight European countries
-
- Mitropoulos, Dionysios (author)
- Natl & Kapodistrian Univ Athens, Dept Urol 1, Med Sch, Athens, Greece.
-
- Chlosta, Piotr (author)
- Jagiellonian Univ, Dept Urol, Krakow, Poland.
-
- Häggman, Michael (author)
- Uppsala universitet,Urologkirurgi
-
show more...
-
- Ström, Torbjörn (author)
- Ipsen Sweden, Med Dept, Stockholm, Sweden.
-
- Markussis, Vyron (author)
- Ipsen Greece, Med Dept, Athens, Greece.
-
show less...
-
Natl & Kapodistrian Univ Athens, Dept Urol 1, Med Sch, Athens, Greece Jagiellonian Univ, Dept Urol, Krakow, Poland. (creator_code:org_t)
- POLISH UROLOGICAL ASSOC, 2021
- 2021
- English.
-
In: CENTRAL EUROPEAN JOURNAL OF UROLOGY. - : POLISH UROLOGICAL ASSOC. - 2080-4806 .- 2080-4873. ; 74:2, s. 161-168
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.5...
-
show less...
Abstract
Subject headings
Close
- Introduction: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC).Material and methods: A survey using a 28-item, structured, quantitative questionnaire about the management of patients with PC was conducted in eight European countries between February and May 2018. Survey recipients were selected from a private database of healthcare providers.Results: Overall, 375 physicians completed the survey (response rate, 58%). Participants were urologists (71.2%) or medical oncologists (28.8%), with a mean practice duration of 19.9 years and with university hospital or cancer center (41.6%), non-teaching hospital (38.4%) or private-sector clinic (20.0%) affiliations. Median proportions of physicians considering ADT as monotherapy to treat patients with PC in different risk groups varied between countries, but overall were: high/very high-risk, 60%; intermediate-risk, 30%; low-risk, 7.5%. The use of ADT monotherapy in the different risk groups also varied by medical specialty and type of affiliation. Proportions of participants applying different target thresholds for testosterone (T) levels also varied by country, but overall were: <50 ng/dL, 29.9%; <32 ng/dL, 4.8%; <20 ng/dL, 54.3%; castration but no specific target, 11%. More than half of participants (58.7%) determined target T levels only when prostate-specific antigen level was increased.Conclusions: Our multinational survey provides evidence that PC management varies across European countries and with clinical context, and frequently diverges from European Association of Urology (EAU) - European Society for Radiotherapy and Oncology (ESTRO) - European Society of Urogenital Radiology (ESUR) - International Society of Geriatric Oncology (SIOG) guidelines. Strategies for effective implementation of evidence-based recommendations in clinical practice may be needed to optimize patient outcomes.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Keyword
- prostate cancer
- androgen deprivation therapy
- castration levels
- European Association of Urology guidelines
- testosterone
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database